Member Info for HedgeHogarth

Apologies for my grammar - re-reading my post would suggest English is not my first language. I just can't type and not one to review ahead of pressing 'post'

Not that is matter - but i can assure you that English is not only my first language, its probably my only language.

Merci beaucoup x

LOL - half awake on a Friday morning and though that December post was from Santa!

Let's hope Santa has those diamonds in his sack

For me, what is announced today or soon after is pivotal. If banks don't call in the debt now - the evidence they have on the diamonds and other assets belonging to VAST must be very real, very genuine and within sight.

The BANK are no fools, infact Banks are more prudent than any of us on this BB. If they plan to call in the loan - they know that the sooner they do it, the more successful they will be in recovering something.

Point 1

ColdFishPie - What a great name - I love it (Just hope you are not also using it as a password ;-)

Point 2

ColdFishPie is spot on - great post o'Socialist one. Refreshingly honest and very very consistent with my thoughts on the current situation. Only wish i had spare funds to top-up

Ilovemycombover - I'll give you the benefit of the doubt and assume you are not one of those here with an agens

You are probably correct - based on the last week or so

However - my advice for those invested or considering an investment here is this. Don't confude the current share price activity with the value of the company. Consider this:

In the last 5 session the share price has reduce by 25% - knocking £5m off the mCAP. However,only c2% of the issues shares have actually changed hands.

The value of this company has not changed in the last 10 days; all that has happened is that BT had a sniff but chose not to bid. There can be lots of reasons why they didn't. Having worked in Corporate all my life - I can assure you that the hurdles to jump to get a decision made are numerous - and very, very high when it comes to parting with 10s of £millions. Their strategy team will have identified MMAG as 1 option to fuel their future success in re-commerce - they will have had other options too. If, seemingly, their interest in MMAG is over, it does not make MMAG a bad company, it just means they have favoured a different option for any number of reasons.

But, consider this, does the fact that they were sniffing around MMAG in the first place not interest shareholders?

It's been eerily quite on this forum - no a bad sign as I love building positions before the herd arrive

It would be great to hear from others who have genuine thoughts and views - as opposed to the doom mongers who appear to be here with an agenda

I'm not selling a single share; to sell now is effectively saying I value this business at less than 2x EBITDA

1 year ago Natwest were happy to lend them £30m at a time when it was easier to get a kiss from Lady Gaga that for a small business to secure funding (Which they happily extended terms on recently, Q2 2023)

They continue to meet expectations

" strong momentum seen in Q2 has thus far been carried into the early part of Q3 of our 2023 financial year and this combined with the focus on gross margin by continuing to buy for less and sell for more, and cost savings introduced, mean the Board is confident of the Group meeting its full year expectations".

RNS: 13th July

Oh, and a sudden dip in SP is a little strange and probably a sign that something is happening behind the scenes in my mind. In relative terms, this SP was fairly stable ahead of the announcement of takeover

We know that Music Magpie is 'effectively' up for sale, we can see what the going rate 'premiums' have been for companies this year (even on distressed ones!). More than 80% of Music Magpie is now focused on Consumer Tech Re-commerce. Re-commerce as a category is booming - we have a whole new generation who are big fans of 2nd hand items to reduce waste, bag a bargain and feel great

Just my opinion - DYOR

Fortunate to see some market data on Consumer Technology Re-commerce - looked very positive indeed and I'm sure is putting a smile on the face of MMAG CEO

It all about expectations.....

One year ago, I was feeling pretty much the same as I do now - excited at making that big step from pre-clinical to clinical Biotech.

The SP is now 2.35p, one year ago it was 1.3p

(So while it has been a terribly frustrating year, my portfolio is up significantly as a result of +80% growth in HEMO)

I'm not sure any of us know enough or are qualified enough to know whether any of the additional wait to start clinical trials was avoidable - my gut feel is very little. It is what it is.

Whilst I still feel the SP hugely undervalues Hemo; small companies across the board are undervalues given the state of the equity markets and economy in the last 2 years. Hemo have progressed in that year, 2 great updates on CBR and we now have Prevail on board. However, 1 year on, we still cannot be sure when trials will start.

The RNS this week though confirmed that Hemo are doing everything they can to meet their ambitious timelines - including spending incremental money to expedite things.

We should have 3-4 significant market proven catalysts within weeks - It will be these pivotal events that give this share the best chance of a re-rate, and a big one at that.

I hope, I pray, I think that it is just a matter of further patience and time for my loyalty to be rewarded.

And If I'm wrong - maybe I could earn some pocket money as a paid troll on LSE. I feel like I've learnt more than enough from those who have poisoned this board over the last 4 years.

The two most powerful warriors are patience and time. – Leo Tolstoy (War and Peace)

I imagine it may be a bit of placing churn

I'm past caring.

Maybe Bob's being paid, maybe he's not.

Maybe Bob is an expert in patent law, maybe he is not. Do I want to read about patents in the detail he shares, no I don't.

Rightly or wrongly I trust that the company will do everything it can to protects it's IP. If it is not successful with patent, I assume it will explore other ways to retains it - like the good Colonel's secret recipe.

I will make a dignified exit and leave this troubled forum to the rest of you.

Good luck to the good ones ,👍

IMO - apologies if i have offended anyone or got this wrong.

Bobssocks, Flecky, Bobcat, DSFlat

I imagine "Tim nice but dim" types working in the city - collaborating

I should have added - "im my opinion" and based on my personal observations and those of others

Says it all....

Bobcat - in his own words "Next time we are pumping"

Collective manipulation

Disgusting behaviour and very sad that it is allowed to go on - condoned by LSE

I imagine one day we will wake up and find that LSE forums are offline - pending full enquiry

I agree 100% with you HT

Micky - very few people think the same as you

Surely the RNS updates on CBR etc give you the confidence that this is very much a Hemo asset

Woodcut - a bit of patience and I have no doubt the price at which you missed selling at will come around again

Apologies - I meant a 12mth low given my analysis below.

And before you correct me - I think it touched 14.5, so give or take a 12mth low

Need?

DrDeo - not the first and you wont be the last to have a pop at the Vlad as CEO.

As I have said before, I'm a fan and like the fact that the CEO is the founder - with all the passion, commitment and drive that comes with it. Hemo is Vlad's obsession - and it's success will double up as Vlad's success. Him and his wife have a lot of skin in the game with c10% of the company - that cannot be said for all small businesses. Their future and their child's future is dependant on the commercial success of Hemogenyx.

Here's an interesting article i would recommend on Founders as CEOs - the suggestion is that Biotech founders tend to relinquish the reins at the 'point of commercialisation'. (Definition below)

https://alitamaseb.medium.com/founding-ceo-vs-hired-ceo-what-the-data-reveals-eaaf20b7616e

The commercialisation of a new product is considered the final stage of new product development (NPD). At this point production, distribution, marketing, sales, customer support, and other key functions are needed to ensure commercial success. For Biotech this could be seen as completion of Phase 3 or possibly during Ph 2 for some drugs and therapies